Trials that use: Interim analysis / alpha spending
New to this method? Read the tutorial →
11,819 results
- TESmTBIIndependent statistical analysis of Transcranial Electrical Stimulation for mTBI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03244475).
- TESSERACTIndependent statistical analysis of Transcranial Direct Current Stimulation as a Neuroprotection in Acute Stroke: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03574038).
- TESSERACT-BAIndependent statistical analysis of Transcranial Direct Current Stimulation as a Neuroprotection in Acute Stroke Before and After Thrombectomy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Testing a Neurocognitive Model of Distancing Using Transcranial Magnetic Stimulation.: Complete Statistical AnalysisIndependent statistical analysis of Testing a Neurocognitive Model of Distancing Using Transcranial Magnetic Stimulation.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03698591).
- Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer: Complete Statistical AnalysisIndependent statistical analysis of Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer:…
- Testing Adaptive Interventions to Improve Physical Activity for Sedentary Women: Complete Statistical AnalysisIndependent statistical analysis of Testing Adaptive Interventions to Improve Physical Activity for Sedentary Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03558828).
- Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body: Complete Statistical AnalysisIndependent statistical analysis of Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body: primary endpoint results, effect estimate…
- Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I): Complete Statistical AnalysisIndependent statistical analysis of Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W): Complete Statistical AnalysisIndependent statistical analysis of Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F): Complete Statistical AnalysisIndependent statistical analysis of Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G): Complete Statistical AnalysisIndependent statistical analysis of Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- TEsting for Arterial Disease in Diabetes (TrEAD) Study: Complete Statistical AnalysisIndependent statistical analysis of TEsting for Arterial Disease in Diabetes (TrEAD) Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04058626).
- Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH – Subprotocol Z1K): Complete Statistical AnalysisIndependent statistical analysis of Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1): Complete Statistical AnalysisIndependent statistical analysis of Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH – Subprotocol Z1C): Complete Statistical AnalysisIndependent statistical analysis of Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Testing the Ability of JNJ-18038683 to Improve Cognition and Reduce Depressive Symptoms in Stable Bipolar Patients: Complete Statistical AnalysisIndependent statistical analysis of Testing the Ability of JNJ-18038683 to Improve Cognition and Reduce Depressive Symptoms in Stable Bipolar Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC): Complete Statistical AnalysisIndependent statistical analysis of Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC): primary endpoint results,…
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer,…
- Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors: Complete Statistical AnalysisIndependent statistical analysis of Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors: primary endpoint results, effect estimate with confidence interval,…
- Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma: Complete Statistical AnalysisIndependent statistical analysis of Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma: primary endpoint results,…
- Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval,…
- Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial: Complete Statistical AnalysisIndependent statistical analysis of Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone: Complete Statistical AnalysisIndependent statistical analysis of Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the…
- Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma: Complete Statistical AnalysisIndependent statistical analysis of Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma: primary endpoint results, effect…
- Testing the Effectiveness of a Falls Prevention System: Complete Statistical AnalysisIndependent statistical analysis of Testing the Effectiveness of a Falls Prevention System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03678402).
- Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer: Complete Statistical AnalysisIndependent statistical analysis of Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian,…
- Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma: Complete Statistical AnalysisIndependent statistical analysis of Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma:…
- Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH – Subprotocol J): Complete Statistical AnalysisIndependent statistical analysis of Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J): primary endpoint results, effect estimate…
- Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer: primary endpoint results, effect estimate with confidence interval,…
- Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer: Complete Statistical AnalysisIndependent statistical analysis of Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Testosterone Gel in Preventing Weakness Caused by Steroid Therapy in Men With Glioma: Complete Statistical AnalysisIndependent statistical analysis of Testosterone Gel in Preventing Weakness Caused by Steroid Therapy in Men With Glioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Testosterone Replacement in Men With Diabetes and Obesity: Complete Statistical AnalysisIndependent statistical analysis of Testosterone Replacement in Men With Diabetes and Obesity: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01127659).
- Tetra-NIRS Clinical Study: Complete Statistical AnalysisIndependent statistical analysis of Tetra-NIRS Clinical Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00871975).
- Tetrahydrobiopterin in Patients With Chronic Kidney Disease (CKD) and Albuminuria: Complete Statistical AnalysisIndependent statistical analysis of Tetrahydrobiopterin in Patients With Chronic Kidney Disease (CKD) and Albuminuria: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00625820).
- TEXTIndependent statistical analysis of Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- TEXT-TKRIndependent statistical analysis of A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery: primary endpoint results, effect estimate with…
- TextFluenza: Using Technology To Promote Flu Vaccination In Underserved Maternal And Child Populations: Complete Statistical AnalysisIndependent statistical analysis of TextFluenza: Using Technology To Promote Flu Vaccination In Underserved Maternal And Child Populations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Texting to Promote Breastfeeding (TOPS): Complete Statistical AnalysisIndependent statistical analysis of Texting to Promote Breastfeeding (TOPS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06375655).
- Texture Analysis for Postmenopausal Osteoporosis: Complete Statistical AnalysisIndependent statistical analysis of Texture Analysis for Postmenopausal Osteoporosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00145977).
- TF-EATIndependent statistical analysis of Trauma-Focused Equine-Assisted Therapy (TF-EAT) for Veterans With PTSD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03068325).
- THC-ADIndependent statistical analysis of Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02792257).
- The ‘MADe IT’ Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis: Complete Statistical AnalysisIndependent statistical analysis of The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- The Aging Endocrine Pancreas: Characterization of the Entero-insular Axis Physiology in the Elderly: Complete Statistical AnalysisIndependent statistical analysis of The Aging Endocrine Pancreas: Characterization of the Entero-insular Axis Physiology in the Elderly: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- The Angel® Catheter Pivotal Clinical Trial: Complete Statistical AnalysisIndependent statistical analysis of The Angel® Catheter Pivotal Clinical Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02186223).
- The Articulated Oral Airway as an Aid to Mask Ventilation: Complete Statistical AnalysisIndependent statistical analysis of The Articulated Oral Airway as an Aid to Mask Ventilation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03144089).
- The Association Between Peri-Operative Hyperglycemia and Major Morbidity and Mortality: Complete Statistical AnalysisIndependent statistical analysis of The Association Between Peri-Operative Hyperglycemia and Major Morbidity and Mortality: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00487162).
- The Bihormonal iLet Bionic Pancreas Feasibility Study: Complete Statistical AnalysisIndependent statistical analysis of The Bihormonal iLet Bionic Pancreas Feasibility Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03840278).
- The BROADEN Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Partial Lipodystrophy: Complete Statistical AnalysisIndependent statistical analysis of The BROADEN Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Partial Lipodystrophy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…